Committee Meeting October 18, 2012, from 8 a.m. to 5p.m. (Day 2 of 2)
Agenda: The committee will discuss new drug application (NDA) 203568, mipomersen injection, by Genzyme Corporation. The proposed indication (use) is as an adjunct to maximally tolerated lipid-lowering medications and diet to reduce low-density lipoprotein (LDL) cholesterol, apolipoprotein B, total cholesterol, non-high density lipoprotein-cholesterol and lipoprotein (a) in patients with homozygous familial hypercholesterolemia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment